Glonghui May 12 丨 Microchip Biology (688321)(688321pennfierce3sizes.SH) Announcementpennfierce3sizes, the company recently received the "Acceptance Notice" issued by the Center for Drug Evaluation of the State Food and Drug Administration (known as the "Center for Drug Evaluation of the State Food and Drug Administration") for the registration of domestically produced drugs. A randomized, open-label, controlled, multicentre, phase III clinical trial of cidarabamide combined with cinderimab and bevacizumab in the treatment of advanced microsatellite stable or complete mismatch repair (MSS/pMMR) colorectal cancer that failed ≥2 lines of standard treatment was accepted by the Center for Drug Evaluation of the State Food and Drug Administration.
